Global sacral nerve stimulation market to reach USD 634.1M by 2030
The global sacral nerve stimulation market, valued at $422.7 million in 2023, is on a trajectory of rapid expansion, with projections indicating it will soar to $634.1million by 2030, growing at a compound annual growth rate (CAGR) of 6% from 2023 to 2030, as per a recent report by Coherent Market Insights. Owing to various advantages offered by minimally invasive procedures such as lesser pain, reduced risk of infection, shorter recovery time, and minimal scarring, there has been a significant increase in their adoption across various clinical applications over the recent past. Sacral nerve stimulation is a minimally invasive procedure requiring only a small incision to place the electrode lead in the sacral foramen.
Market dynamics:
The global sacral nerve stimulation market is witnessing significant growth due to increasing prevalence of overactive bladder and urge incontinence globally. According to the National Association for Continence, over 25 million Americans experience overactive bladder which is a progressive disease and more than 50% of the Americans between ages of 40 to 60 years are affected by overactive bladder. Further, rise in geriatric population and surge in obesity rates globally are also contributing to the increasing burden of overactive bladder. Obesity is one of the major risk factors for overactive bladder as it puts extra pressure on the bladder leading to improper bladder functioning.
Market trends:
Rise in demand for minimally invasive procedures for urinary incontinence and development of novel stimulation devices are major market trends in global sacral nerve stimulation market. Minimally invasive procedures such as sacral nerve stimulation are often preferred over conventional surgical procedures due to benefits such as lesser pain, minimal scarring and faster recovery time. Further, introduction of technology advances such as recently launced tined leads for sacral nerve stimulation by Medtronic and Axonics which improve patient comfort and minimize complications are strengthening the market growth.
Market opportunities:
The implantable SNS devices segment is expected to remain the most dominant segment over the forecast period owing to rising preference for permanent solutions to treat urinary incontinence and fecal incontinence. These devices provide long lasting treatment effects without requiring repeat surgery.
The external SNS devices segment is expected to witness lucrative growth owing to their advantage of being non-invasive and offering patients and physicians the option to trial therapy before committing to implantable devices. This reduces healthcare costs and helps higher patient acceptance rates. Coherent Market Insights
